| Dear Oxford Club Member Reader, Today I'm going to scold you a little bit... But then I'm going to do something very positive for you. First, the scolding. On May 2 of last year, we sent out a message to all Oxford Club Members with the details on a tiny biotech stock that Alexander Green was recommending in his Oxford Microcap Trader service. It was called ImmunoGen (Nasdaq: IMGN). ImmunoGen had developed an FDA approved treatment for ovarian cancer. And Alex was highlighting it as a small cap with big potential. Now, the unfortunate part was 99% of you ignored his message. Only 1 out of 100 chose to listen to Alex. Which was a big shame because the very next day ImmunoGen more than doubled from $5 to over $10 on promising financial results. But that was just the beginning. By the end of the year, ImmunoGen was bought by AbbVie (NYSE: ABBV) for $10.1 billion. And ImmunoGen shot up to around $29... a near 500% gain in about 6 months. 
However, there is good news. If you missed out on ImmunoGen, Alex has something for you. To make sure you and others don't miss the next big winner, today he's giving away a new small cap stock recommendation in his new microcap strategy session. It's a gold stock that is growing dramatically. Earnings jumped 1,195% year over year in the latest earnings release. Alex reveals the ticker symbol for free here He'll also give you his entire formula for picking microcap stocks, which you are welcome to use for yourself. All you have to do is access his Microcap Millionaire Academy right here. Sincerely, Nicole P.S. The small cap portfolio Alex will teach you is specifically designed to work in any market environment. In historical testing, it grew a portfolio 6 times faster than the market and generated a total return of 3,679% over the past 25 years. Go here to get every metric needed to build this portfolio. | 
No comments:
Post a Comment